The first matrix metalloproteinase (MMP) was discovered in 1962 from the tail of a tadpole by
its ability to degrade collagen. As their name suggests, matrix metalloproteinases are …

In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …

Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of
the central nervous system, and the leading cause of nontraumatic neurological disability in …

Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …

In most cases, multiple sclerosis (MS) begins with a relapsing-remitting course followed by
insidious disability worsening that is independent from clinically apparent relapses and is …

Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that
involves demyelination and axonal degeneration. Although substantial progress has been …

In contrast to the multiple disease-modifying therapies that are available for relapsing–
remitting multiple sclerosis (MS), the therapeutic options for progressive MS (PMS) are …

Epidemiology and Pathophysiology of Multiple Sclerosis : CONTINUUM: Lifelong Learning in
Neurology Account Register Activate Subscription Help Subscribe American Academy of …

There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

In the last decades, evidence suggesting the direct or indirect involvement of B cells on
multiple sclerosis (MS) pathogenesis has accumulated. The increased amount of data on …